Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/32039982/ below:

Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer

Practice Guideline

Affiliations

• ¹ Veterans Affairs San Diego Healthcare System, San Diego, California.
• ² University of California-San Diego, Division of Gastroenterology La Jolla, California.
• ³ Moores Cancer Center, La Jolla, California.
• ⁴ Division of Gastroenterology, Department of Medicine, Oregon Health and Science University, Portland, Oregon.
• ⁵ Veterans Affairs Medical Center, White River Junction, Vermont.
• ⁶ The Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
• ⁷ University of Connecticut Health Center, Farmington, Connecticut.
• ⁸ Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio.
• ⁹ Veterans Affairs Puget Sound Health Care System, Seattle, Washington.
• ¹⁰ University of Washington School of Medicine, Seattle, Washington.
• ¹¹ San Francisco Veterans Affairs Medical Center, San Francisco, California.
• ¹² University of California San Francisco, San Francisco, California.
• ¹³ Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota.
• ¹⁴ University of Minnesota, Minneapolis, Minnesota.
• ¹⁵ Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
• ¹⁶ Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, Massachusetts.
• ¹⁷ Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.

• PMID: 32039982
• PMCID: PMC7393611
• DOI: 10.14309/ajg.0000000000000544

Item in Clipboard

Practice Guideline

Samir Gupta et al. Am J Gastroenterol. 2020 Mar.

• ¹ Veterans Affairs San Diego Healthcare System, San Diego, California.
• ² University of California-San Diego, Division of Gastroenterology La Jolla, California.
• ³ Moores Cancer Center, La Jolla, California.
• ⁴ Division of Gastroenterology, Department of Medicine, Oregon Health and Science University, Portland, Oregon.
• ⁵ Veterans Affairs Medical Center, White River Junction, Vermont.
• ⁶ The Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
• ⁷ University of Connecticut Health Center, Farmington, Connecticut.
• ⁸ Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio.
• ⁹ Veterans Affairs Puget Sound Health Care System, Seattle, Washington.
• ¹⁰ University of Washington School of Medicine, Seattle, Washington.
• ¹¹ San Francisco Veterans Affairs Medical Center, San Francisco, California.
• ¹² University of California San Francisco, San Francisco, California.
• ¹³ Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota.
• ¹⁴ University of Minnesota, Minneapolis, Minnesota.
• ¹⁵ Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
• ¹⁶ Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, Massachusetts.
• ¹⁷ Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.

• PMID: 32039982
• PMCID: PMC7393611
• DOI: 10.14309/ajg.0000000000000544

Item in Clipboard

No abstract available

PubMed Disclaimer

Conflicts of interest The authors disclose no conflicts of interest relative to the current work since 2016. Industry relationships for authors (consulting, research, reimbursement) without conflict of interest relevant to the current work since 2016: Douglas K. Rex (Olympus, Boston Scientific, Covidien, Lumendi, Salix, Aries, Cook Medical, ERBE, Bausch Health Inc, Novo Nordisk, Endochoice, Braintree Laboratories, Norgine, Endokey, EndoAid, Medivators, Satisfai Health); Sapna Syngal (Chirhoclin, Cook, Myriad Genetics, Inc, DC Health, Inc); David Lieberman (Covidien, Freenome Holdings, Inc, Ironwood, Check-Cap, CEGX); Douglas Robertson (Covidien, Freenome Holdings, Inc, Amadix); Tonya Kaltenbach (Aries Pharmaceuticals, Micro-Tech Endoscopy, Olympus, Boston Scientific, Medtronic); Aasma Shaukat (None); Samir Gupta (Freenome Holdings, Inc, Guardant Health, Inc, Mallinckrodt Pharmaceuticals); Carol Burke (Salix Pharmaceuticals, Ferring Pharmaceuticals, Aries Pharmaceuticals, Intuitive Surgical, Pfizer, Covidien, Boston Scientific, US Endoscopy, Abbvie Cancer Prevention Pharmaceuticals, Janssen Pharmaceuticals; SLA Pharma AG; Freenome Holdings, Inc). Jason Dominitz (None); Joseph C. Anderson (None).

Recommendations for follow-up after colonoscopy…

Recommendations for follow-up after colonoscopy and polypectomy. Recommendations for post-colonoscopy follow-up in average…

Recommendations for follow-up after colonoscopy and polypectomy. Recommendations for post-colonoscopy follow-up in average risk adults are depicted. After high-quality colonoscopy defined by examination complete to cecum adequate to detect polyps >5 mm, performed by a colonoscopist with adequate ADR with complete polyp resection, risk-stratified repeat colonoscopy intervals are provided. SSP, sessile serrated polyp/sessile serrated adenoma/sessile serrated lesion.

Risk for metachronous advanced neoplasia…

Risk for metachronous advanced neoplasia among individuals with normal colonoscopy, 1–2 adenomas <10 mm in size, or high-risk adenoma (adenoma >10…10>

Risk for metachronous advanced neoplasia among individuals with normal colonoscopy, 1–2 adenomas <10 mm in size, or high-risk adenoma (adenoma >10 mm in size, adenoma with tubulovillous/villous histology, adenoma with high-grade dysplasia or ≥3 adenomas <10 mm) based on a meta-analysis of 10,139 across 8 surveillance studies is depicted. Risk for metachronous adenoma among individuals with no adenoma or 1–2 small adenomas is similar, and much lower than risk among individuals with baseline high-risk adenoma. In studies that defined high risk as advanced adenoma alone (n = 4 studies), cumulative advanced adenoma risk was 16% (95% CI, 9%–25%), and in studies that defined high risk as advanced adenoma or ≥3 adenomas <10 mm (n = 4 studies), cumulative advanced adenoma risk was 19% (95% CI, 10%–30%; C Dube, personal communication, September 18, 2018).

• Endoscopic Removal of Colorectal Lesions: Recommendations by the US Multi-Society Task Force on Colorectal Cancer.

  Kaltenbach T, Anderson JC, Burke CA, Dominitz JA, Gupta S, Lieberman D, Robertson DJ, Shaukat A, Syngal S, Rex DK. Kaltenbach T, et al. Am J Gastroenterol. 2020 Mar;115(3):435-464. doi: 10.14309/ajg.0000000000000555. Am J Gastroenterol. 2020. PMID: 32058340 No abstract available.

• Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer.

  Gupta S, Lieberman D, Anderson JC, Burke CA, Dominitz JA, Kaltenbach T, Robertson DJ, Shaukat A, Syngal S, Rex DK. Gupta S, et al. Gastrointest Endosc. 2020 Mar;91(3):463-485.e5. doi: 10.1016/j.gie.2020.01.014. Epub 2020 Feb 7. Gastrointest Endosc. 2020. PMID: 32044106 Free PMC article. No abstract available.

• Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer.

  Gupta S, Lieberman D, Anderson JC, Burke CA, Dominitz JA, Kaltenbach T, Robertson DJ, Shaukat A, Syngal S, Rex DK. Gupta S, et al. Gastroenterology. 2020 Mar;158(4):1131-1153.e5. doi: 10.1053/j.gastro.2019.10.026. Epub 2020 Feb 7. Gastroenterology. 2020. PMID: 32044092 Free PMC article. No abstract available.

• Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps: Recommendations of the US Multi-Society Task Force on Colorectal Cancer.

  Shaukat A, Kaltenbach T, Dominitz JA, Robertson DJ, Anderson JC, Cruise M, Burke CA, Gupta S, Lieberman D, Syngal S, Rex DK. Shaukat A, et al. Gastroenterology. 2020 Nov;159(5):1916-1934.e2. doi: 10.1053/j.gastro.2020.08.050. Epub 2020 Nov 4. Gastroenterology. 2020. PMID: 33159840 Review. No abstract available.

• Assessment of volumetric growth rates of small colorectal polyps with CT colonography: a longitudinal study of natural history.

  Pickhardt PJ, Kim DH, Pooler BD, Hinshaw JL, Barlow D, Jensen D, Reichelderfer M, Cash BD. Pickhardt PJ, et al. Lancet Oncol. 2013 Jul;14(8):711-20. doi: 10.1016/S1470-2045(13)70216-X. Epub 2013 Jun 7. Lancet Oncol. 2013. PMID: 23746988 Free PMC article.

• High Positive Predictive Value of Multitarget Stool DNA After Aerodigestive Tract Radiotherapy.

  Ebner DW, Eckmann JD, Burger KN, Mahoney DW, Whitaker TJ, Petersen IA, Kisiel JB. Ebner DW, et al. Gastro Hep Adv. 2022;1(5):746-754. doi: 10.1016/j.gastha.2022.05.002. Epub 2022 May 16. Gastro Hep Adv. 2022. PMID: 36117548 Free PMC article.

• Colorectal Cancer Screening: An Updated Modeling Study for the US Preventive Services Task Force.

  Knudsen AB, Rutter CM, Peterse EFP, Lietz AP, Seguin CL, Meester RGS, Perdue LA, Lin JS, Siegel RL, Doria-Rose VP, Feuer EJ, Zauber AG, Kuntz KM, Lansdorp-Vogelaar I. Knudsen AB, et al. JAMA. 2021 May 18;325(19):1998-2011. doi: 10.1001/jama.2021.5746. JAMA. 2021. PMID: 34003219 Free PMC article.

• Faecal immunochemical test outside colorectal cancer screening?

  Pin-Vieito N, Puga M, Fernández-de-Castro D, Cubiella J. Pin-Vieito N, et al. World J Gastroenterol. 2021 Oct 14;27(38):6415-6429. doi: 10.3748/wjg.v27.i38.6415. World J Gastroenterol. 2021. PMID: 34720531 Free PMC article. Review.

• The Addition of Other Fecal Biomarkers Does Not Improve the Diagnostic Accuracy of Immunochemical Fecal Occult Blood Test Alone in a Colorrectal Cancer Screening Cohort.

  Hijos-Mallada G, Lué A, Velamazan R, Saura N, Abril C, Lorenzo M, Navarro M, Chueca E, Arechavaleta S, Gomollón F, Lanas Á, Sostres C. Hijos-Mallada G, et al. Front Med (Lausanne). 2021 Jun 4;8:665786. doi: 10.3389/fmed.2021.665786. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34150803 Free PMC article.

• Randomized Trial of Facilitated Adherence to Screening Colonoscopy vs Sequential Fecal-Based Blood Test.

  Zauber AG, Winawer SJ, O'Brien MJ, Mills GM, Allen JI, Feld AD, Jordan PA, Fleisher M, Orlow I, Meester RGS, Lansdorp-Vogelaar I, Rutter CM, Knudsen AB, Mandelson M, Shaukat A, Mendelsohn RB, Hahn AI, Lobaugh SM, Soto Palmer B, Serrano V, Kumar JR, Fischer SE, Chen JC, Bayuga-Miller S, Kuk D, O'Connell K, Church TR. Zauber AG, et al. Gastroenterology. 2023 Jul;165(1):252-266. doi: 10.1053/j.gastro.2023.03.206. Epub 2023 Mar 21. Gastroenterology. 2023. PMID: 36948424 Free PMC article. Clinical Trial.

1. 1. Heitman SJ, Ronksley PE, Hilsden RJ, et al. Prevalence of adenomas and colorectal cancer in average risk individuals: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009;7:1272–1278. - PubMed
2. 1. Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2012;143:844–857. - PubMed
3. 1. Kahi CJ, Boland CR, Dominitz JA, et al. Colonoscopy surveillance after colorectal cancer resection: recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2016;150:758–768. e11. - PubMed
4. 1. Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. Am J Gastroenterol 2014;109:1159–1179. - PubMed
5. 1. Kahi CJ, Boland CR, Dominitz JA, et al. Colonoscopy surveillance after colorectal cancer resection: recommendations of the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol 2016;111:337–346. quiz 347. - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3